{
    "clinical_study": {
        "@rank": "58627", 
        "acronym": "SPRIX", 
        "arm_group": [
            {
                "arm_group_label": "Sprix /Placebo", 
                "arm_group_type": "Experimental", 
                "description": "Sprix 31.5 mg single dose nasal spray and Placebo"
            }, 
            {
                "arm_group_label": "Sumatriptan/placebo", 
                "arm_group_type": "Experimental", 
                "description": "Sumatriptan 20 mg single dose nasal spray and placebo"
            }, 
            {
                "arm_group_label": "SRIX placebo/Sumatriptan placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "single dose SPRIX placebo,Single dose Sumatriptan placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators propose to test the efficacy of ketorolac nasal spray versus sumatriptan\n      nasal spray versus placebo for acute abortive therapy of migraine head pain as well as for\n      migraine associated symptoms including nausea and allodynia."
        }, 
        "brief_title": "Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Migraines", 
        "condition_browse": {
            "mesh_term": "Migraine Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion/Exclusion Criteria\n\n        At the Screening Visit, a subject must meet the following criteria to participate in this\n        study:\n\n        1.18-65 years of age 2.Fulfills International Classification of Headache Disorders\n        (ICHD)-II Criteria of migraine as noted below in Table 1 3.History of migraines for at\n        least one year 4.Migraine onset prior to the age of 50 years of age 5.Headache frequency\n        (of any headaches, migraine or non-migraine) < 9 days per month 6.At visit 2, participants\n        must report between 1-9 migraine attacks during the 28-day run-in period on the headache\n        diary. 7.At least 48 hours of freedom from headache between treated migraine attacks. 8.If\n        currently using headache preventive medications, must be on a stable dose for at least 3\n        months prior to enrollment and throughout the study period and be on no more than one\n        prophylactic agent. 9.Able to complete all study procedures, including the questionnaire\n        (assessing demographics, headache characteristics, headache comorbidities and medical\n        history at the initial visit and headache characteristics) and the required headache\n        calendars, and all study visits; 10.Able to understand, read and sign an informed consent\n        (English).\n\n        Exclusion Criteria:\n\n          1. Any condition (history or presence of) which contraindicates the use of triptans or\n             NSAIDs including:\n\n               -  Known hypersensitivity or intolerance to triptans or NSAIDs\n\n               -  Contraindications to triptan use (uncontrolled hypertension, ischemic heart\n                  disease, prinz-metal angina, cardiac arrhythmias, multiple risk factors for\n                  atherosclerotic vascular disease, primary vasculopathies, and basilar and\n                  hemiplegic migraine)\n\n               -  Cerebrovascular disease except for mild non-specific white matter disease\n\n               -  Peripheral vascular disease or any other ischemic disease including myocardial\n                  infarction\n\n               -  Uncontrolled hypertension (systolic BP 160 mmHg or diastolic BP 95 mmHg or\n                  (both)\n\n               -  Migraine aura fulfilling ICHD-II criteria for hemiplegic or basilar-type\n                  migraine\n\n               -  Any history of chronic renal or hepatic impairment\n\n               -  Use of an ergotamine-containing medication or monamine oxidase inhibitor\n\n               -  Known or suspected pregnancy, negative pregnancy test\n\n               -  Lactation\n\n               -  Bleeding dsycrasias including gastritis, peptic ulcer disease,gastrointestinal\n                  bleeding\n\n          2. Physician diagnosis of any pain syndrome other than migraine\n\n          3. Classification as treatment resistant by investigator\n\n          4. Known drug or substance abuse\n\n          5. Any opioid use in past 2 months\n\n          6. Use of any medication, which could interfere with study assessments\n\n          7. History of noncompliance with taking medication;\n\n          8. Use of any experimental drug or device within 30 days prior to the Screening Visit\n             (Visit 1);\n\n          9. Any abnormal finding or condition deemed clinically significant by the investigator\n             on history, screening, or physical exam that contraindicates the use of triptans or\n             NSAIDs or that might interfere with the patient's safety, study participation, or\n             which might confound the interpretation of the study results.\n\n         10. Any history of chronic renal or hepatic disease already excluded above under number\n             1; plus see exclusion 9.\n\n         11. History of chronic pulmonary disorder including nasal polyps (see 1) and asthma.\n\n         12. History of upper respiratory infection or other respiratory tract condition that\n             could interfere with the absorption of the nasal spray or with assessment of AEs\n             including rhinitis medicamentosa (chronic daily use of topical decongestants).\n\n         13. History of nasal surgery."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807234", 
            "org_study_id": "NA00075486"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sprix /Placebo", 
                "description": "single dose of Sprix nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack. three migraine attacks total during a study period of 3 months.", 
                "intervention_name": "SPRIX", 
                "intervention_type": "Drug", 
                "other_name": "ketorolac"
            }, 
            {
                "arm_group_label": "Sumatriptan/placebo", 
                "description": "Sumatriptan 20 mg one single dose of nasal spray for an acute migraine attack. three migraine attacks total during a study period of 3 months.", 
                "intervention_name": "Sumatriptan", 
                "intervention_type": "Drug", 
                "other_name": "zolmitriptan"
            }, 
            {
                "arm_group_label": [
                    "Sprix /Placebo", 
                    "Sumatriptan/placebo", 
                    "SRIX placebo/Sumatriptan placebo"
                ], 
                "description": "SPRIX placebo one spray in each nostril and Sumatriptan placebo one nasal spray.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "normal saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ketorolac", 
                "Ketorolac Tromethamine", 
                "Sumatriptan", 
                "Zolmitriptan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 7, 2013", 
        "location": {
            "contact": {
                "email": "lpeterlin@jhmi.edu", 
                "last_name": "Barbara L Peterlin, D.O.", 
                "phone": "410-550-9550"
            }, 
            "contact_backup": {
                "email": "lwhite@jhmi.edu", 
                "last_name": "Linda W White, CRNP", 
                "phone": "410-550-4418"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21224"
                }, 
                "name": "The Johns Hopkins Bayview Headache Center"
            }, 
            "investigator": {
                "last_name": "Barbara L Peterlin, DO", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Efficacy of Ketorolac Nasal Spray (Sprix\u00ae) as Compared to Sumatriptan Nasal Spray and Placebo for the Acute Abortive Treatment of Migraine", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary endpoints will be proportion of patients who achieve pain relief (where pain relief is defined as reduction in pain from moderate to severe pain (4-10/10 on numerical rating scale) to none or mild pain (0-3/10 on numerical rating scale)  Secondary endpoints include proportion of patients pain-free at 2 hours and those who were symptom free from migraine associated symptoms at 2 hrs; proportion of patients with sustained pain relief (SPR) and sustained pain freedom (SPF) at 24 hours; time to pain relief during the 2-hour period; proportion of patients\nwith pain relief at 20 minutes and proportion of those who achieve relief of migraine associated symptoms (eg photophobia, phonophobia, nausea, and allodynia) at 2 hours post-treatment with no rescue medication use prior to the 2 hour time point. SPR/SPF from 2-24 hours will be defined as the proportion of patients reporting pain relief or pain-freedom respectively at 2 hours which was maintained from 2-24 hours with no rescue", 
            "measure": "Primary endpoints will be the proportion of patients who achieve pain relief 4-10/10 on numerical rating scale) to none or mild pain (0-3/10 on numerical rating scale).", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807234"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Drs Barbara Peterlin", 
            "investigator_title": "Director, The Johns Hopkins Bayview Headache Research", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "collaborator": {
                "agency": "Luitpold Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}